[Ip-health] INVITATION- "How much does the EC pay for tubercolosis R&D- MSF launch report- European Parliament Nov 12th, 12:30-2pm

[Alexandra HEUMBER]

[ Converted text/html to text/plain ]


The Honourable Members of the European Parliament

Carl Schlyter MEP (Green party- Sweden),

Dorette Corbey MEP (PSE- Netherlands),

Luisa Morgantini MEP (GUE/NGL - Italy),

Antonios Trakatellis MEP (EPP-Greece) (tbc)



are pleased to host the launch of a report by M=E9decins Sans Fronti=E8res:



?How much does the European Commission pay

for tuberculosis R&D?



12:30-2pm, Wednesday 12th November 2008

European Parliament,  Room   A5G2

Sandwiches will be provided





Chair Carl Schlyter, MEP



Opening remarks Luisa Morgantini, MEP



How much does the European Commission pay for tuberculosis R&D?

Presentation of the MSF Access for essential medicines Campaign Report by

Dr. Tido von Schoen-Angerer, Director, MSF Access Campaign

and Spring Gombe, MSF Access Campaign



Respondents:

Prof. Stewart Cole, Head of Laboratories, EPFL (tbc)

Dr. Frauke Jochims, TB advisor, M=E9decins Sans Fronti=E8res





Discussion



Closing remarks Dorette Corbey, MEP





A recent report[1][1] notes how ?Europe?s research funding situation is a
jigsaw puzzle of complexity, lack of transparency, lack of coordination, an=
d
lack of clear priorities. With few exceptions most of the rich EU countries
were not in a position to either report on or increase their investments in=
 TB
research.?



M=E9decins Sans Fronti=E8res has explored the European Commission?s contrib=
ution,
and analyses why funding dedicated to R&D for neglected diseases such as TB=
 is
still grossly insufficient in comparison to the need.   Why so?  What would
the EC?s fair share be?  How can funding streams be improved so that the mo=
ney
matches the needs?  What needs to happen?



Join us to discuss these and other crucial questions.

Please RSVP confirming your attendance to mai.do@paris.msf.org before Novem=
ber
6, 2008.

---------------------------------------------------------------------------=
---

[1][2] Treatment Action Group. TB R&D: A critical Analysis of funding trend=
s
2005-2006
____________________________________
Alexandra Heumber
IP Policy Adviser
M=E9decins Sans Fronti=E8res
Access to Essential Medicines Campaign
Rue Dupr=E9, 94. 1090 Brussels
++32 (0) 2 474 75 09 (Dir off)
++ 32 (0) 479 514 900 (Mob)
++ 32 (0) 2 474 75 75 (Fax)

=3D=3D=3DReferences:=3D=3D=3D
  1. #_ftn1
  2. #_ftnref1